{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T02:25:35Z","timestamp":1762050335212,"version":"3.41.2"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There are limited data on clinical outcomes associated with the use of bebtelovimab for the treatment of coronavirus disease 2019 (COVID\u201019) among cancer patients. We aimed to define the clinical characteristics and outcomes among patients receiving bebtelovimab as part of the COVID\u201019 therapeutics program at our cancer center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective cohort study of immunosuppressed adult patients who received bebtelovimab at Fred Hutchinson Cancer Center between March 2022, and November 2022. We reviewed medical records to capture the date of the first positive COVID\u201019 test, clinical characteristics, outcomes, and follow\u2010up COVID\u201019 testing for 60 days after the first positive. Persistent infection was defined as a positive test beyond day 30; these patients were reviewed beyond day 60.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 93 patients who received bebtelovimab, 64 (69%) had hematologic malignancy. Sixty\u2010nine (74%) patients received bebtelovimab within 2 days after diagnosis. Two (2%) patients were hospitalized, none required ICU care, and one patient died on day 52; although it is unknown if death was directly related to COVID\u201019. Ten (11%) patients had persistent COVID\u201019 infection; of these, four received additional COVID\u201019 therapy with either nirmatrelvir\/ritonavir or remdesivir, and five out of six patients with sequencing data available had spike protein mutations associated with bebtelovimab resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A coordinated systems\u2010based approach led to prompt initiation of bebtelovimab within two days of testing positive in most patients. We observed few hospitalizations or deaths. Persistent infection was noted in 11% of patients with four requiring additional therapies, highlighting a need for novel strategies to manage immunosuppressed patients.\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/tid14223-gra-0001-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text><\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.14223","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T04:18:21Z","timestamp":1704773901000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcomes and frequency of persistent infection among immunosuppressed patients treated with bebtelovimab for COVID\u201019 infection at an ambulatory cancer center"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6917-7156","authenticated-orcid":false,"given":"Eduardo","family":"Sanchez","sequence":"first","affiliation":[{"name":"Division of Allergy and Infectious Diseases University of Washington  Seattle Washington USA"},{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M","family":"Krantz","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Yoke","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases University of Washington  Seattle Washington USA"},{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Gallaher","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases University of Washington  Seattle Washington USA"},{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"So","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases University of Washington  Seattle Washington USA"},{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra Kassamali","family":"Escobar","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"},{"name":"School of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Tverdek","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"},{"name":"School of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A","family":"Rosen","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases University of Washington  Seattle Washington USA"},{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZZ","family":"Quinn","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Swetky","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Walji","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"McCreery","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"McCulloch","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases University of Washington  Seattle Washington USA"},{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Weixler","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavitra","family":"Roychoudhury","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"},{"name":"School of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5196","authenticated-orcid":false,"given":"Steven A","family":"Pergam","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases University of Washington  Seattle Washington USA"},{"name":"Fred Hutchinson Cancer Center  Seattle Washington USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.01.022"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012251"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac571"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(20)30429\u20104"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13792"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad306"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001578\u20101"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18385"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)00163\u20105"},{"key":"e_1_2_10_11_1","unstructured":"Fact sheet for healthcare providers: Emergency use authorization for bebtelovimab. February 11 2022. Accessed September 5 2023.https:\/\/www.fda.gov\/media\/156152\/download"},{"volume-title":"FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region","year":"2022","author":"Research C for DE and","key":"e_1_2_10_12_1"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000841"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40472\u2010022\u201000385\u2010y"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00605\u201022"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.05.007"},{"key":"e_1_2_10_17_1","unstructured":"Coronavirus Disease 2019 (COVID\u201019) Treatment Guidelines. Accessed September 5 2023.https:\/\/files.covid19treatmentguidelines.nih.gov\/guidelines\/covid19treatmentguidelines.pdf"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004278"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac565"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac411"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13901"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac346"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac517"},{"key":"e_1_2_10_24_1","unstructured":"GrazianiL GoriL ManciulliT et\u00a0al.Successful use of nirmatrelvir\/ritonavir in immunocompromised patients with persistent and\/or relapsing COVID\u201019."},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102021\u2010245992"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2021.100057"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa446"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac847"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac601"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac802"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000603"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.14223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T06:35:04Z","timestamp":1721198104000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.14223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/tid.14223"],"URL":"https:\/\/doi.org\/10.1111\/tid.14223","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"type":"print","value":"1398-2273"},{"type":"electronic","value":"1399-3062"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"2023-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14223"}}